WTO Price Transparency Talks Face Resistance From Developed Countries
Executive Summary
Last week the World Trade Organization’s TRIPS Council discussed transparency in medicine pricing, including R&D costs.
You may also be interested in...
With $46m, i2o Takes Up The Challenge Of Winning Approval For ITCA 650
The Boston biotech raises series A cash and succeeds Intarcia as the sponsor of the GLP-1 drug/device combination product for type 2 diabetes, subject of two FDA complete response letters.
Drug Pricing ‘Not Appropriate Topic’ For WTO TRIPS Council
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
New Italian Pricing Decree To Drive R&D Transparency
Following on from moves to push price transparency on to the global agenda, Italy is poised to pass a decree that would oblige companies to disclose public R&D funding.